Skip to main content

FDA Approvals

Keytruda First Cancer Drug Approved for Any Solid Tumor Based on a Biomarker Instead of Tumor Site

Imfinzi a New PD-L1 Approved for Bladder Cancer After Platinum-Based Chemotherapy

Alunbrig, an Oral Kinase Inhibitor, Receives FDA Approval for NSCLC with ALK Mutation

Rydapt First Drug in Decades Approved by the FDA for Acute Myeloid Leukemia

Stivarga First Drug in a Decade Approved by the FDA for Liver Cancer

Atezolizumab Approved as First-Line Treatment for Advanced Bladder Cancer in Some Patients

Bavencio, a PD-L1 Inhibitor, First Nonchemotherapy Drug Approved for Merkel-Cell Carcinoma

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL

Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Page 16 of 21
Results 151 - 160 of 202